Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04450290
Other study ID # MED-EL_CRD_2014_02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2020
Est. completion date May 5, 2022

Study information

Verified date May 2022
Source MED-EL Elektromedizinische Geräte GesmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma. The aim of this clinical investigation is to obtain a first experience in use of the investigational device in the adult clinical population, and to initially assess tools, techniques and performance outcome measures that may be considered in future clinical studies of similar devices.


Description:

The principal objective of this study is to exploratively investigate the safety profile of the device which will be evaluated through the analysis of adverse events during the follow-up period. For the study to be considered a success, the results of the adverse event analysis shall never cause an unbalanced risk vs. benefit assessment. The secondary objectives of this study aim at investigating the usefulness of possible outcome measures in evaluating the performance of the device.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 5, 2022
Est. primary completion date May 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Minimum age of eighteen (18) years at time of enrolment. - Severe to profound sensorineural hearing loss on the ipsilateral ear. - A functional auditory nerve in the ear to be implanted. - Subjects reporting to having used an optimally fit hearing aids for a minimum of three months before the decision that a cochlear implant (CI) is the preferential option. - Cochlea anatomy compatible with the insertion of a +FLEX28 electrode array. - Compatibility with a soft surgery approach as per clinical practice at the site. - Post-lingual hearing impairment. - Subject fulfilling indication criteria for a CI according to the local professional standards, as reported by the implanting surgeon. - General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study and realistic expectations, as deemed appropriate by the implanting surgeon. - Signed and dated informed consent before the start of any study-specific procedure. Exclusion Criteria: - Lack of compliance with any inclusion criterion. - Previously having received a cochlear implant on the ear chosen for placing the IMD (Investigational Medical Device). - Evidence of ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or might cause increased risk of infection (e.g. dysplastic cochlea), as confirmed by medical examination and/or as per CT/MRT (Computed Tomography/Magnetic Resonance Tomography). - Evidence of anatomic abnormalities that would prevent appropriate placement of the stimulator housing in the bone of the skull. - Evidence of otosclerosis. - Known allergic reaction or intolerance to the materials used in the implant (including medical grade silicone, platinum, iridium, parylene c, dexamethasone). - Known absence of cochlear development or if the cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway. - Evidence of active external or middle ear infection or history of recurrent middle ear infection in the ear to be implanted. - Evidence of perforated tympanic membrane in the ear to be implanted. - Patient reporting immunosuppressive therapy or corticosteroids therapy in the 4 weeks before enrolment. - Evidence of concomitant use of medicinal substances that, in the opinion of the investigator, could alter the therapeutic efficacy of dexamethasone. - Unwillingness or inability of the candidate to comply with all investigational requirements. - Evidence of medical contraindications to surgery of the middle and inner ear and anaesthesia. - Additional disabilities that would prevent or restrict participation in the audiological and medical evaluations required of the clinical investigation.

Study Design


Intervention

Device:
CIDEXEL implant
The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.

Locations

Country Name City State
Germany MHH - Medizinische Hochschule Hannover Hannover

Sponsors (1)

Lead Sponsor Collaborator
MED-EL Elektromedizinische Geräte GesmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events Safety profile of the device which will be evaluated through the analysis of adverse events 10 months
Secondary IFT (Impedance Field Telemetry) - impedance Impedance Field Telemetry and derived values 10 months
Secondary Electrically Evoked Compound Action Potential Electrically Evoked Compound Action Potential and derived values 10 months
Secondary MCL (Maximum Comfortable Loudness) Maximum Comfortable Loudness Levels and Thresholds 10 months
Secondary THR (Threshold) Thresholds 10 months
Secondary PTA (Pure Tone Audiometry) Audiometrical values Results from PTA assessment 10 months
Secondary Hearing Preservation rate Rate of Hearing Preservation according to Skarzynski et al. 10 months
Secondary HSM (Hochmair-Schulz-Moser Sentence) Test Speech test in noise 10 months
Secondary Questionnaire Surgical feedback questionnaire 10 months
See also
  Status Clinical Trial Phase
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Not yet recruiting NCT05973669 - MED-EL Remote Care Multi-Center Feasibility Study N/A
Completed NCT04601909 - FX-322 in Adults With Age-Related Sensorineural Hearing Loss Phase 1
Active, not recruiting NCT04479761 - Sensory Integration of Auditory and Visual Cues in Diverse Contexts N/A
Recruiting NCT05043207 - A Study Protocol for the Validation of UAud in a Clinical Setting. N/A
Recruiting NCT04066270 - Inventory of Radiological and Vestibular Function in Cochlear Implant Candidates
Recruiting NCT04070937 - Correlation of Radiological Lesions With Vestibular Function in Patients With Bilateral Vestibulopathy
Completed NCT03512951 - Subjective Evaluation of a Sound Processing Method for Hearing Aids on Auditory Distance Perception N/A
Completed NCT05855005 - Direct-to-Consumer Hearing Aids and Listening Effort N/A
Recruiting NCT05599165 - Speech Perception in Bimodal Hearing N/A
Completed NCT05101083 - Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids N/A
Completed NCT05521308 - Investigating Hearing Aid Frequency Response Curves N/A
Completed NCT05072457 - Benefit of Assistive Listening Device for Lateralization N/A
Recruiting NCT05776459 - Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) Phase 2
Completed NCT05086276 - FX-322 in Adults With Acquired Sensorineural Hearing Loss Phase 2
Recruiting NCT06058767 - Preschool Hearing Screening N/A
Completed NCT05180630 - Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems N/A
Completed NCT03613909 - Acceptance of the CP950 Sound Processor N/A
Active, not recruiting NCT03352154 - Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants N/A
Completed NCT04629664 - FX-322 in Adults With Severe Sensorineural Hearing Loss Phase 1